WASHINGTON - Rep. John J. Moakley, D-Mass., chairman of the House Rules Committee that will reconcile the various health care reform bills, last week sent to President Clinton a letter strongly opposing the Breakthrough Drug Advisory Council provision of the Health Security Act.

Specifically, Moakley warned that the breakthrough committee would have several "unintended adverse effects" on the biotechnology industry: